Friday, 16 October 2026European Markets

VRANKEN-POMMERY And REMY COINTREAU Have A High Dividend Yield And Return On Equity In The Beverages—Wineries & Distilleries Industry.

Loading stream...

(vianews) - vranken-pommery (vrap.pa) is among this list of stock assets with the highest dividend rate and return on equity on the beverages—wineries & distilleries industry.

financial asset price forward dividend yield return on equity
vranken-pommery (vrap.pa) €17.90 4.27% 2.59%
remy cointreau (rco.pa) €155.55 1.4% 17.18%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. vranken-pommery (vrap.pa)

4.27% forward dividend yield and 2.59% return on equity

vranken-pommery monopole société anonyme produces and sells wines and champagnes in europe, north america, and the asia pacific. the company offers its products under the champagne charles lafitte, champagne demoiselle, champagne pommery, champagne heidsieck & c° monopole, champagne vranken – diamant, champagne germain, sao pedro, rozès, and grifo brands. vranken-pommery monopole société anonyme was founded in 1976 and is headquartered in reims, france.

earnings per share

as for profitability, vranken-pommery has a trailing twelve months eps of €1.14.

pe ratio

vranken-pommery has a trailing twelve months price to earnings ratio of 15.7. meaning, the purchaser of the share is investing €15.7 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 2.59%.

volume

today's last reported volume for vranken-pommery is 1147 which is 42.41% below its average volume of 1992.

yearly top and bottom value

vranken-pommery's stock is valued at €17.90 at 02:40 est, under its 52-week high of €19.10 and way above its 52-week low of €15.70.

sales growth

vranken-pommery's sales growth for the current quarter is 0.2%.

dividend yield

according to morningstar, inc., the next dividend payment is on jul 11, 2023, the estimated forward annual dividend rate is 0.8 and the estimated forward annual dividend yield is 4.27%.

more news about vranken-pommery.

2. remy cointreau (rco.pa)

1.4% forward dividend yield and 17.18% return on equity

rémy cointreau sa, together with its subsidiaries, engages in the production, sale, and distribution of liqueurs and spirits. the company operates through rémy martin, liqueurs & spirits, and partner brands segments. it offers liqueurs, brandy, gin, single malt whisky, rum, wine, and champagne primarily under the cointreau, metaxa, st-rémy, mount gay, bruichladdich, port charlotte, octomore, the botanist, westland, louis xiii, and domaine des hautes glaces brands. the company operates in europe, the middle east, africa, the americas, asia, australia, and new zealand. rémy cointreau sa was founded in 1724 and is headquartered in cognac, france.

earnings per share

as for profitability, remy cointreau has a trailing twelve months eps of €5.7.

pe ratio

remy cointreau has a trailing twelve months price to earnings ratio of 27.29. meaning, the purchaser of the share is investing €27.29 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.18%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, remy cointreau's stock is considered to be oversold (<=20).

moving average

remy cointreau's worth is higher than its 50-day moving average of €145.04 and under its 200-day moving average of €160.20.

volume

today's last reported volume for remy cointreau is 19596 which is 73.86% below its average volume of 74988.

more news about remy cointreau.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com